Press Releases

Rheumatoid Arthritis Drugs Market to Expand at a CAGR of 2.96% from 2018 to 2030

The global rheumatoid arthritis drugs market was valued at US$ 19597.43 mn in 2016. Taking into consideration the factors associated with the growth of the rheumatoid arthritis drugs market, it is anticipated to expand at a CAGR of 2.96% from 2018 to 2030

Rheumatoid Arthritis Drugs Market: Overview

The rheumatoid arthritis drugs market expects a good turnover across the forecast period of 2018-2026 due to the increasing prevalence of rheumatoid arthritis among the global populace. Rheumatoid arthritis is a condition that affects the joints of the hand, wrists, ankles, and knees. It is categorized as a systemic disease as it also affects the respiratory and cardiac system. It is usually prevalent among the elderly and largely affects the female population. The symptoms of rheumatoid arthritis are warmth, redness, and swelling of the affected areas. Statistics highlight that 41 people out of 10000 people are diagnosed with rheumatoid arthritis.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111994

The rheumatoid arthritis drugs market may gain an upper hand in growth mainly due to the escalating use of over-the-counter medications rather than surgeries or operations for treating rheumatoid arthritis. The drugs developed for curing rheumatoid arthritis can enhance prognosis and mobility greatly and serve as a boon for the patients. The aforementioned factors may bring great growth opportunities for the rheumatoid arthritis drugs market.

The COVID-19 outbreak may have minimal impact on the rheumatoid arthritis drugs market as the pharmaceutical sector is ruled out of the lockdown norms by the government. The production of drugs remains largely unaffected as the pharma sector is fully functional without any restrictions. Therefore, this factor may have a minimal negative influence on the rheumatoid arthritis drugs market. However, the post-lockdown era may assure stable growth for the rheumatoid arthritis drugs market.

The global rheumatoid arthritis drugs market was valued at US$ 19597.43 mn in 2016. Taking into consideration the factors associated with the growth of the rheumatoid arthritis drugs market, it is anticipated to expand at a CAGR of 2.96% from 2018 to 2026. The use of rheumatoid arthritis drugs to decrease joint damage and enhance the overall body functioning may serve as great growth generators for the rheumatoid arthritis drugs market.

Biologics Segment to Gain Considerable Momentum

Based on drug type, the rheumatoid arthritis drugs market can be segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), anti-rheumatic drugs (DMARDs), biologic drugs, and corticosteroids. The biologics segment may acquire a significant share of the rheumatoid arthritis drugs market due to the advancements in biotechnological research. The spike in the use of biological drugs may also serve as a growth multiplier for the rheumatoid arthritis drugs market.

Hospital Pharmacy Segment to Contribute Significantly, Online Pharmacy to Gain Good Traction

In terms of the distribution channel, the rheumatoid arthritis drugs market can be classified into online pharmacy, retail pharmacy, and hospital pharmacy. Hospital pharmacy is estimated to observe good growth. Online pharmacy may also acquire a substantial growth share. The COVID-19 outbreak may serve as the prominent growth factor for the online pharmacy segment. Due to the growing transmission of the novel coronavirus and the stay-at-home orders by governments of various countries, many consumers are opting for online pharmacy methods to get their medicines at home.

View full report@ https://qyresearchmedical.com/report/rheumatoid-arthritis-drugs-market-drug-type-disease-modifying-anti-rheumatic-drugs-dmards-non-steroidal-anti-inflammatory-drugs-nsaids-corticosteroids-biologic-response-modifiers-biologics-distribution-018-2030/111994

Key Players to Gain Largely Due to Mergers and Acquisition Activities

Many key players are involved in activities such as mergers, acquisitions, joint ventures, partnerships, and collaborations to cement their base among all the competitors. This aspect eventually serves as a growth generator for the rheumatoid arthritis drugs market. The investment of prominent players in research and development activities may harness growth for the rheumatoid arthritis drugs market. Some well-entrenched players in the rheumatoid arthritis drugs market are Novartis AG, Hoffman-La Roche Ltd., Bristol-Myers Squibb Company, Pfizer Inc., and Eli Lilly and Company.

Use of Rheumatoid Arthritis Drugs in Treating COVID-19 May Serve As a Game-Changer for Growth

The novel coronavirus pandemic has created havoc across the globe with its escalating fatalities and high transmission rate. The race to find a vaccine or treatment for recovering from COVID-19 is in full force. Various governments and organizations are pumping investments in research and development activities. The potential of existing drugs to cure COVID-19 is also being explored by researchers and scientists.

Rheumatoid arthritis drugs are being tested for curing COVID-19. Tocilizumab, an immunosuppressive drug used for the treatment of rheumatoid arthritis is being tested. Another drug, baricitinib, used for treating rheumatoid arthritis is also being tested. If these tests are successful, they can turn the tables of growth for the rheumatoid arthritis drugs market.

Quick regulatory approvals and government support to fuel growth prospects of rheumatoid arthritis drugs market

The rheumatoid arthritis drugs market may gain largely from quick approvals for drugs from regulatory bodies like the FDA and the support of government through funding and legislation is anticipated to bring great growth prospects for the rheumatoid arthritis drugs market.

Asia Pacific to Emerge As Significant Growth Contributor

Geographically, the rheumatoid arthritis drugs market is segmented into North America, Latin America, the Middle East and Africa, Asia Pacific, and Europe. Asia Pacific is expected to emerge as a prominent market shareholder in terms of region. The accelerating healthcare expenditure and the presence of an extensive distribution system may bring good growth for the rheumatoid arthritis drugs market.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111994/2900

Small players are entering the rheumatoid arthritis drugs market, ultimately leading to a boost in the growth rate. Prominent key players are bolstering growth for the rheumatoid arthritis drugs market due to consumer loyalty. Low-cost manufacturing costs have led to a rise in production facilities related to pharmaceutical and biological organizations across India and China. North America may record a moderate rate due to the growing prevalence of rheumatoid arthritis and huge investments in the healthcare sector.

The global rheumatoid arthritis drugs market has been segmented as given below:

Drug Type

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
  • Corticosteroids
  • Disease Modifying Anti-rheumatic Drugs (DMARDs)
  • Biologic Response Modifiers (Biologics)

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC countries
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Rheumatoid Arthritis Drugs Market: Market Snapshot

4. Market Overview
4.1. Global Rheumatoid Arthritis Drugs Market: Product Overview
4.2. Global Rheumatoid Arthritis Drugs Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rheumatoid Arthritis Drugs Market Revenue Projections, 2016–2026
4.5. Porter’s Five Forces Analysis

5. Market Outlook
5.1. Pipeline analysis
5.2. Brand Analysis
5.3. Key Mergers and Acquisitions

6. Global Rheumatoid Arthritis Drugs Market Analysis, by Drug Type
6.1. Key Findings
6.2. Introduction
6.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
6.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Drug Type
6.4.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
6.4.2. Corticosteroids
6.4.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.4.4. Biologic Response Modifiers (Biologics)
6.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type

7. Global Rheumatoid Arthritis Drugs Market Analysis, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channels
7.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Distribution Channel
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channels

8. Global Rheumatoid Arthritis Drugs Market Analysis, by Region
8.1. Key Findings
8.2. Global Rheumatoid Arthritis Drugs Market Scenario, by Country
8.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region
8.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Region
8.4.1. North America
8.4.2. Europe
8.4.3. Asia Pacific
8.4.4. Latin America
8.4.5. Middle East & Africa
8.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region

9. North America Rheumatoid Arthritis Drugs Market Analysis
9.1. Key Findings
9.2. North America Rheumatoid Arthritis Drugs Market Overview
9.3. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
9.4. North America Rheumatoid Arthritis Drugs Market Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
9.6. North America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
9.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
9.6.2. Corticosteroids
9.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
9.6.4. Biologic Response Modifiers (Biologics)
9.7. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
9.8. North America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
9.8.1. Hospital Pharmacy
9.8.2. Retail Pharmacy
9.8.3. Online Pharmacy
9.9. North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis

10. Europe Rheumatoid Arthritis Drugs Market Analysis
10.1. Key Findings
10.2. Europe Rheumatoid Arthritis Drugs Market Overview
10.3. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
10.4. Europe Rheumatoid Arthritis Drugs Market Forecast, by Country
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
10.6. Europe Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
10.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
10.6.2. Corticosteroids
10.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
10.6.4. Biologic Response Modifiers (Biologics)
10.7. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
10.8. Europe Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
10.8.1. Hospital Pharmacy
10.8.2. Retail Pharmacy
10.8.3. Online Pharmacy
10.9. Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis

11. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis
11.1. Key Findings
11.2. Asia Pacific Rheumatoid Arthritis Drugs Market Overview
11.3. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
11.4. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
11.6. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
11.6.2. Corticosteroids
11.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.6.4. Biologic Response Modifiers (Biologics)
11.7. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
11.8. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Pharmacy
11.9. Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis

12. Latin America Rheumatoid Arthritis Drugs Market Analysis
12.1. Key Findings
12.2. Latin America Rheumatoid Arthritis Drugs Market Overview
12.3. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
12.4. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
12.6. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
12.6.2. Corticosteroids
12.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.6.4. Biologic Response Modifiers (Biologics)
12.6.5. Enteral needles
12.7. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
12.7.1. Hospital Pharmacy
12.7.2. Retail Pharmacy
12.7.3. Online Pharmacy
12.8. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.9. Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis

13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Rheumatoid Arthritis Drugs Market Overview
13.3. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
13.4. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Country
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East and Africa
13.5. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
13.6. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
13.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
13.6.2. Corticosteroids
13.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.6.4. Biologic Response Modifiers (Biologics)
13.7. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
13.8. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Pharmacy
13.9. Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis

14. Competitive Landscape
14.1. Company Profiles
14.1.1. AbbVie, Inc.
14.1.1.1. Company Details
14.1.1.2. Business Overview
14.1.1.3. Financial Overview
14.1.1.4. Strategic Overview
14.1.1.5. SWOT Analysis
14.1.2. Janssen Biotech, Inc.
14.1.2.1. Company Details
14.1.2.2. Business Overview
14.1.2.3. Financial Overview
14.1.2.4. Strategic Overview
14.1.2.5. SWOT Analysis
14.1.3. Amgen, Inc.
14.1.3.1. Company Details
14.1.3.2. Business Overview
14.1.3.3. Financial Overview
14.1.3.4. Strategic Overview
14.1.3.5. SWOT Analysis
14.1.4. Pfizer, Inc.
14.1.4.1. Company Details
14.1.4.2. Business Overview
14.1.4.3. Financial Overview
14.1.4.4. Strategic Overview
14.1.4.5. SWOT Analysis
14.1.5. Novartis AG
14.1.5.1. Company Details
14.1.5.2. Business Overview
14.1.5.3. Financial Overview
14.1.5.4. Strategic Overview
14.1.5.5. SWOT Analysis
14.1.6. Sanofi S.A.
14.1.6.1. Company Details
14.1.6.2. Business Overview
14.1.6.3. Financial Overview
14.1.6.4. Strategic Overview
14.1.6.5. SWOT Analysis
14.1.7. F. Hoffmann-La Roche Ltd.
14.1.7.1. Company Details
14.1.7.2. Business Overview
14.1.7.3. Financial Overview
14.1.7.4. Strategic Overview
14.1.7.5. SWOT Analysis
14.1.8. Merck & Co.
14.1.8.1. Company Details
14.1.8.2. Business Overview
14.1.8.3. Financial Overview
14.1.8.4. Strategic Overview
14.1.8.5. SWOT Analysis
14.1.9. Bristol-Myers Squibb Company
14.1.9.1. Company Details
14.1.9.2. Business Overview
14.1.9.3. Financial Overview
14.1.9.4. Strategic Overview
14.1.9.5. SWOT Analysis
14.1.10. Eli Lilly and Company
14.1.10.1. Company Details
14.1.10.2. Business Overview
14.1.10.3. Financial Overview
14.1.10.4. Strategic Overview
14.1.10.5. SWOT Analysis

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111994/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button